Cholangitis Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Cholangitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 55 trials

Recruiting

Unraveling the Mechanisms Underlying Primary Sclerosing Cholangitis Through a Multidisciplinary, Integrative Research Approach

Primary Sclerosing Cholangitis
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)143 enrolled1 locationNCT04685200
Recruiting
Phase 2

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis

Primary Biliary CholangitisPBC
Mirum Pharmaceuticals, Inc.260 enrolled130 locationsNCT05050136
Recruiting

A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

Primary Biliary Cholangitis
Ipsen424 enrolled65 locationsNCT06447168
Recruiting
Phase 3

A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis (PBC)
Ipsen276 enrolled177 locationsNCT06016842
Recruiting
Phase 3

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

Primary Biliary Cholangitis
Gilead Sciences318 enrolled191 locationsNCT06051617
Recruiting

Liver-gut Axis Study Through Identification of Liver Disease-specific Microbiome

Non-Alcoholic Fatty Liver DiseaseAutoimmune HepatitisPrimary Sclerosing Cholangitis+2 more
Chungnam National University Hospital3,000 enrolled1 locationNCT06519162
Recruiting
Phase 1Phase 2

A Two-part Study to Investigate the Effects in Adults of Two Doses of Golexanolone in Patients With Primary Biliary Cholangitis (PBC) With Fatigue and Cognitive Dysfunction

Primary Biliary Cholangitis (PBC)
Umecrine Cognition AB84 enrolled36 locationsNCT07304843
Recruiting
Phase 1

A Study of TAK-781 in Healthy Volunteers and in Participants With Non-Cirrhotic Primary Sclerosing Cholangitis (PSC)

Healthy VolunteersPrimary Sclerosing Cholangitis
Takeda134 enrolled1 locationNCT07229911
Recruiting

Biochemical Response and Clinical Outcomes in Patients With PBC

Primary Biliary CholangitisPrimary Biliary Cholangitis (PBC)
RenJi Hospital3,000 enrolled1 locationNCT07449793
Recruiting
Early Phase 1

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

Inflammatory Bowel DiseasesPrimary Sclerosing Cholangitis
Stanford University15 enrolled1 locationNCT05912387
Recruiting

Characterization of Biliary Cell-derived Organoids From Bile of PSC and Non-PSC Patients

CholangiocarcinomaPrimary Sclerosing CholangitisPSC
Mayo Clinic300 enrolled1 locationNCT04753996
Recruiting

Biobank for Cholestatic Liver Diseases.

Liver CancerCholangiocarcinomaPrimary Sclerosing Cholangitis+1 more
Mayo Clinic9,150 enrolled1 locationNCT03445585
Recruiting
Phase 2

Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis

Acute Cholangitis
National University of Malaysia172 enrolled1 locationNCT07407491
Recruiting
Phase 3

Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis
Zydus Therapeutics Inc.150 enrolled28 locationsNCT06427395
Recruiting
Phase 3

Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis

Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases150 enrolled7 locationsNCT05751967
Recruiting
Phase 3

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study

Primary Biliary Cholangitis (PBC)
Xijing Hospital of Digestive Diseases150 enrolled1 locationNCT06755541
Recruiting
Phase 3

Fenofibrate in Primary Biliary Cholangitis: a Real World Study

Primary Biliary Cholangitis (PBC)
Xijing Hospital of Digestive Diseases300 enrolled1 locationNCT06755151
Recruiting
Phase 2Phase 3

Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis

Primary Biliary Cholangitis
Xijing Hospital of Digestive Diseases104 enrolled12 locationsNCT05749822
Recruiting
Phase 3

A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

Primary Biliary Cholangitis
Cascade Pharmaceuticals, Inc135 enrolled41 locationsNCT07282353
Recruiting
Phase 3

FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy

Primary Biliary Cholangitis (PBC)
Xijing Hospital of Digestive Diseases132 enrolled1 locationNCT07296458